Katherine Schaefer was investigating methods for treating the inflammation seen in Crohn's disease and ulcerative colitis when something terrible happened -- she noticed her carefully cultured cells were dead. And then something wonderful happened -- she realized she had stumbled upon a potential new method of attacking cancerous tumors that have become resistant to existing drugs.

Schaefer and her colleagues at the University of Rochester Medical Center in New York were testing a compound called a PPAR-gamma modulator -- a compound never considered a cancer drug, or a drug of any kind really -- when Schaefer made a calculation error and used a lot more of the compound than she should have. And her cells died.

Upon further study, Schaefer found the compound killed just about every possible epithelial tumor cell. These cells line organs such as the colon and also the skin. The compound, that works like taxane drugs but without eventual tumor resistance, also killed colon tumors in mice without making them sick.

The research team, whose findings are published in the journal International Cancer Research, plans more safety tests in mice. And eventually, if their outcomes are promising, they plan to design something they can patent as a new drug -- because they would love to see this disastrous lab experiment one day lead to treatment for cancers of the colon, esophagus, liver, and skin.